Heading Back Home To The Heart

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Once upon a time, the heart was at the center of Big Pharma business. Medicines for blood pressure, clotting, high cholesterol, angina, and infarction drove sales and competition for leadership in the cardiovascular area. That happened largely in the late years of the last century and might have continued well into this one, but instead the trend faded, and the industry failed to keep up the momentum in affairs of the heart. A combination of satisfaction with results of the boom times and lack of further innovation chilled efforts toward additional progress. Heart disease still remains the deadliest disease area in the world. And its deadliest forms, such as heart failure, are every bit as intractable as ever.